ES2686300T3 - Asociación de variaciones genéticas raras recurrentes con el trastorno por déficit de atención e hiperactividad (TDAH) y procedimientos de uso de las mismas para el diagnóstico y tratamiento del mismo - Google Patents
Asociación de variaciones genéticas raras recurrentes con el trastorno por déficit de atención e hiperactividad (TDAH) y procedimientos de uso de las mismas para el diagnóstico y tratamiento del mismo Download PDFInfo
- Publication number
- ES2686300T3 ES2686300T3 ES11820610T ES11820610T ES2686300T3 ES 2686300 T3 ES2686300 T3 ES 2686300T3 ES 11820610 T ES11820610 T ES 11820610T ES 11820610 T ES11820610 T ES 11820610T ES 2686300 T3 ES2686300 T3 ES 2686300T3
- Authority
- ES
- Spain
- Prior art keywords
- adhd
- attention deficit
- hyperactivity disorder
- deficit hyperactivity
- recurrent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 230000007614 genetic variation Effects 0.000 title 1
- 230000000306 recurrent effect Effects 0.000 title 1
- 102100024630 Asc-type amino acid transporter 1 Human genes 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 102100028002 Catenin alpha-2 Human genes 0.000 abstract 1
- 102100024340 Contactin-4 Human genes 0.000 abstract 1
- 102100036966 Dipeptidyl aminopeptidase-like protein 6 Human genes 0.000 abstract 1
- 101000859073 Homo sapiens Catenin alpha-2 Proteins 0.000 abstract 1
- 101000909504 Homo sapiens Contactin-4 Proteins 0.000 abstract 1
- 101000804935 Homo sapiens Dipeptidyl aminopeptidase-like protein 6 Proteins 0.000 abstract 1
- 101001008442 Homo sapiens La-related protein 7 Proteins 0.000 abstract 1
- 101001071437 Homo sapiens Metabotropic glutamate receptor 1 Proteins 0.000 abstract 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 abstract 1
- 101001027295 Homo sapiens Metabotropic glutamate receptor 8 Proteins 0.000 abstract 1
- 101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 abstract 1
- 101000650857 Homo sapiens Small glutamine-rich tetratricopeptide repeat-containing protein beta Proteins 0.000 abstract 1
- 101000807541 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 24 Proteins 0.000 abstract 1
- 102100027436 La-related protein 7 Human genes 0.000 abstract 1
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 abstract 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 abstract 1
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 abstract 1
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 abstract 1
- 102100022223 Neuronal growth regulator 1 Human genes 0.000 abstract 1
- 108091006242 SLC7A10 Proteins 0.000 abstract 1
- 102100027721 Small glutamine-rich tetratricopeptide repeat-containing protein beta Human genes 0.000 abstract 1
- 102100037176 Ubiquitin carboxyl-terminal hydrolase 24 Human genes 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Abstract
Un procedimiento para detectar un riesgo aumentado de desarrollar trastorno por déficit de atención e hiperactividad (TDAH) en un sujeto de ensayo, que comprende, a) proporcionar una muestra de ácido nucleico de dicho sujeto; y b) determinar si dicha muestra contiene al menos una variación en el número de copias (CNV) en cualquiera de los genes seleccionados entre GRM5, GRM7, GRM8, GRM1, NEGR1, DPP6, USP24, SLC7A10, CNTN4, CTNNA2, SGTB/NLN y LARP7, en el que si está presente dicha CNV, dicho sujeto tiene un riesgo aumentado de desarrollar TDAH.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37649810P | 2010-08-24 | 2010-08-24 | |
US201161466657P | 2011-03-23 | 2011-03-23 | |
PCT/US2011/048993 WO2012027491A1 (en) | 2010-08-24 | 2011-08-24 | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2686300T3 true ES2686300T3 (es) | 2018-10-17 |
Family
ID=45723796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11820610T Active ES2686300T3 (es) | 2010-08-24 | 2011-08-24 | Asociación de variaciones genéticas raras recurrentes con el trastorno por déficit de atención e hiperactividad (TDAH) y procedimientos de uso de las mismas para el diagnóstico y tratamiento del mismo |
Country Status (7)
Country | Link |
---|---|
US (4) | US20130203814A1 (es) |
EP (1) | EP2609220B1 (es) |
JP (2) | JP6216486B2 (es) |
AU (3) | AU2011293363A1 (es) |
CA (1) | CA2807505A1 (es) |
ES (1) | ES2686300T3 (es) |
WO (1) | WO2012027491A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6216486B2 (ja) | 2010-08-24 | 2017-10-18 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 低頻度反復性遺伝的変異の注意欠陥多動性障害への関連ならびに診断および治療のためのその使用方法 |
DK2766483T3 (da) | 2011-10-10 | 2022-04-19 | Hospital For Sick Children | Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser |
US11180807B2 (en) | 2011-11-04 | 2021-11-23 | Population Bio, Inc. | Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease |
DK2812452T3 (da) | 2012-02-09 | 2020-06-29 | Population Bio Inc | Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser |
DK2895621T3 (da) | 2012-09-14 | 2020-11-30 | Population Bio Inc | Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande |
EP2900835A4 (en) | 2012-09-27 | 2016-05-11 | Population Diagnotics Inc | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS |
US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
WO2016036403A1 (en) | 2014-09-05 | 2016-03-10 | Population Diagnostics Inc. | Methods and compositions for inhibiting and treating neurological conditions |
IL290993B2 (en) * | 2015-09-08 | 2023-11-01 | Childrens Hospital Philadelphia | Methods for diagnosis and treatment of Tourette syndrome |
KR101792813B1 (ko) * | 2016-01-25 | 2017-11-02 | 서울대학교병원 | 주의력결핍 과잉행동장애 치료제에 대한 치료 반응 예측용 조성물 및 방법 |
US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
WO2018195184A1 (en) | 2017-04-19 | 2018-10-25 | Aevi Genomics Medicine, Inc. | Methods of diagnosing and treating adhd in biomarker positive subjects |
EP4177356B1 (en) | 2018-08-08 | 2024-05-08 | PML Screening, LLC | Methods for assessing risk of developing a viral disease using a genetic test |
CN109182532B (zh) * | 2018-08-16 | 2022-01-04 | 新疆农业大学 | 含ca8基因用于筛选哈萨克马泌乳性状试剂盒及其应用 |
WO2023022976A1 (en) * | 2021-08-16 | 2023-02-23 | University Of Florida Research Foundation, Incorporated | Pharmacogenomics score to make decisions on therapy augmentation in aml |
WO2023240194A1 (en) * | 2022-06-08 | 2023-12-14 | Bionano Genomics, Inc. | Determining b-allele frequency values from optical genome mapping data |
CN114917350B (zh) * | 2022-06-21 | 2023-06-13 | 重庆医科大学附属第二医院 | Cftr增强剂在注意缺陷与多动障碍中的应用及产品 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004523557A (ja) | 2001-02-23 | 2004-08-05 | ジョンズ・ホプキンス・ユニバーシティ | チック、振せん、および関連疾患の治療 |
US20050233321A1 (en) * | 2001-12-20 | 2005-10-20 | Hess John W | Identification of novel polymorphic sites in the human mglur8 gene and uses thereof |
US20070244152A1 (en) * | 2004-03-25 | 2007-10-18 | Lowy Martin T | Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders |
AU2007223036A1 (en) | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
TW200819458A (en) * | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
WO2008118258A2 (en) * | 2007-02-06 | 2008-10-02 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
US9012143B2 (en) * | 2007-04-30 | 2015-04-21 | The Ohio State University Research Foundation | Polymorphisms in genes affecting ace-related disorders and uses thereof |
US20090176740A1 (en) * | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
WO2009105718A1 (en) * | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
WO2010057112A2 (en) * | 2008-11-14 | 2010-05-20 | The Children's Hospital Of Philadelphia | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets |
WO2010057132A1 (en) | 2008-11-14 | 2010-05-20 | The Children's Hospital Of Philadelphia | Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same |
WO2011022312A1 (en) | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Ether benzotriazole derivatives |
JP6216486B2 (ja) | 2010-08-24 | 2017-10-18 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 低頻度反復性遺伝的変異の注意欠陥多動性障害への関連ならびに診断および治療のためのその使用方法 |
US20130225623A1 (en) | 2010-10-27 | 2013-08-29 | Mount Sinai School Of Medicine | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists |
WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
WO2014152965A2 (en) | 2013-03-14 | 2014-09-25 | The Children's Hospital Of Philadelphia | Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets |
US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
AU2015298618A1 (en) | 2014-05-30 | 2016-12-08 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism |
WO2016205348A1 (en) | 2015-06-15 | 2016-12-22 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
IL290993B2 (en) | 2015-09-08 | 2023-11-01 | Childrens Hospital Philadelphia | Methods for diagnosis and treatment of Tourette syndrome |
-
2011
- 2011-08-24 JP JP2013526132A patent/JP6216486B2/ja active Active
- 2011-08-24 CA CA2807505A patent/CA2807505A1/en not_active Abandoned
- 2011-08-24 ES ES11820610T patent/ES2686300T3/es active Active
- 2011-08-24 EP EP11820610.1A patent/EP2609220B1/en active Active
- 2011-08-24 AU AU2011293363A patent/AU2011293363A1/en not_active Abandoned
- 2011-08-24 WO PCT/US2011/048993 patent/WO2012027491A1/en active Application Filing
-
2013
- 2013-02-25 US US13/776,662 patent/US20130203814A1/en not_active Abandoned
-
2016
- 2016-03-07 US US15/063,482 patent/US10844434B2/en active Active
-
2017
- 2017-03-21 AU AU2017201900A patent/AU2017201900B2/en active Active
- 2017-07-05 JP JP2017131686A patent/JP2017222675A/ja active Pending
- 2017-10-09 AU AU2017245271A patent/AU2017245271B2/en active Active
-
2020
- 2020-10-07 US US17/065,506 patent/US20210254160A1/en not_active Abandoned
-
2023
- 2023-03-07 US US18/179,825 patent/US20230407399A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10844434B2 (en) | 2020-11-24 |
US20170009296A1 (en) | 2017-01-12 |
JP6216486B2 (ja) | 2017-10-18 |
EP2609220B1 (en) | 2018-06-27 |
AU2011293363A1 (en) | 2013-02-28 |
AU2017245271B2 (en) | 2019-12-19 |
US20130203814A1 (en) | 2013-08-08 |
US20230407399A1 (en) | 2023-12-21 |
US20210254160A1 (en) | 2021-08-19 |
AU2017245271A1 (en) | 2017-11-02 |
JP2017222675A (ja) | 2017-12-21 |
EP2609220A4 (en) | 2014-01-22 |
CA2807505A1 (en) | 2012-03-01 |
EP2609220A1 (en) | 2013-07-03 |
WO2012027491A1 (en) | 2012-03-01 |
AU2017201900B2 (en) | 2017-10-12 |
AU2017201900A1 (en) | 2017-04-13 |
JP2013535985A (ja) | 2013-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2686300T3 (es) | Asociación de variaciones genéticas raras recurrentes con el trastorno por déficit de atención e hiperactividad (TDAH) y procedimientos de uso de las mismas para el diagnóstico y tratamiento del mismo | |
Fozouni et al. | Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy | |
Nikolac Perkovic et al. | Epigenetics of Alzheimer’s disease | |
Kuznyetsov et al. | Evaluation of a novel non-invasive preimplantation genetic screening approach | |
BRPI0718322A2 (pt) | Métodos para diagnosticar uma suscetibilidade para câncer em um indivíduo humano, para identificar um marcador para o uso na avaliação da suscetibilidade para câncer, para genotipar uma amostra de ácido nucléico, para avaliar um inidivíduo quanto a probabilidade de resposta a um agente terapêutico, para predizer o prognóstico e para monitorar o progresso de um tratamento de um indivíduo, kit para avaliar a suscetibilidade para câncer em um indivíduo, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para câncer em um indivíduo. | |
BR112014020083A8 (pt) | Dispositivos indicadores biológicos de esterilização e métodos de uso | |
ES2530843T3 (es) | Métodos basados en microARN para el diagnóstico de cáncer de páncreas | |
Jagot et al. | Is it worth considering circulating microRNAs in multiple sclerosis? | |
AR088827A1 (es) | Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer | |
CO6511214A2 (es) | Detección del evento das 40278 9 de aad 1 | |
ATE534753T1 (de) | Zusammensetzungen und verfahren zur identifikation eines carbapenemase-gens | |
WO2011142836A3 (en) | Assays for the detection of genotype, mutations, and/or aneuploidy | |
PH12017500798A1 (en) | Pna probes, kits and methods for detecting human papillomavirus genotypes of human papillomavirus | |
BR112012031045A2 (pt) | métodos para detecção de uma condição, para determinar a eficácia de um tratmento terapêutico de uma condição, e para a seleção de um sujeito que sofre de uma condição, e, kit. | |
EA201370070A1 (ru) | СПОСОБ ДЕТЕКЦИИ, ДИФФЕРЕНЦИАЦИИ И КВАНТИФИКАЦИИ ПОПУЛЯЦИЙ Т-КЛЕТОК С ИСПОЛЬЗОВАНИЕМ КОЛИЧЕСТВЕННОЙ ПЦР С ОБРАТНОЙ ТРАНСКРИПЦИЕЙ В РЕАЛЬНОМ ВРЕМЕНИ (ОТ-колПЦР РВ) | |
MX2010002368A (es) | Varolacion rapida de condiciones respiratorias superiores. | |
WO2009149319A3 (en) | Gene expression profiles associated with asthma exacerbation attacks | |
AU2010202926B2 (en) | Markers and methods relating to the assessment of Alzheimer's disease | |
WO2012027483A3 (en) | Defining diagnostic and therapeutic targets of conserved free floating fetal dna in maternal circulating blood | |
BRPI1009276A2 (pt) | painel, kit, dispositivo, método e meio legível por computador para teste diagnóstico rápido para uso na diagnose de malária e infecção bacteriana grave numa amostra de teste | |
NO330943B1 (no) | En metode for detektering og/eller typebestemmelse og/eller kvantifisering av human papillomavirus (HPV) type, primere og prober derav samt diagnostisk sett og anvendelse derav. | |
ES2722900T3 (es) | Portaobjetos para micromatrices y método para detectar algas tóxicas | |
WO2012135620A3 (en) | Molecular gram stain | |
GB201200178D0 (en) | Diagnostic method and system | |
SG168423A1 (en) | Influenza detection method and kit therefor |